A phase 3 study of RM-493 (setmelanotide) to treat Bardet-Biedl Syndrome (BBS).

Trial Profile

A phase 3 study of RM-493 (setmelanotide) to treat Bardet-Biedl Syndrome (BBS).

Planning
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Setmelanotide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Sponsors Rhythm
  • Most Recent Events

    • 19 Mar 2018 According to a Rhythm Pharmaceuticals media release, company expects to start in 2018.
    • 10 Jan 2018 New trial record
    • 04 Jan 2018 According to a Rhythm Pharmaceuticals media release, company expects to meet regulatory authorities in early 2018 to plan this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top